CISH develops a better mouse model for metastatic prostate cancer

Prostate cancer is the most common form of cancer in men, and the second most deadly of all cancers. Yt has research has been striving by imperfect animal models of the disease. Now, a team of researchers led by Associate Professor Mike Rosenmund has developed a new model for rapidly create much better mouse models.

As their teams explain in Cancer Discovery to develop the new model, called RapidCap, they directly induce gene mutations within the prostate model mice developed primary metastatic tumors that metastasize to other sites, in contrast with prior models that did not reliably generate metastatic disease.

When they put the new model to work, the team was excited to discover that a gene called if (diversifies) metastasis: a different path for cancer seeding primary tumors. They treated the mice with a newly discovered drug called (01) that inhibited the amount of Myc in cells. This shrinks the metastases, suggesting, says Tianbin, 'that our model provides an excellent tool for developing new approaches to cure the type of prostate cancer that now is incurable.'

Support autism research at CISH!

Autism spectrum disorders (ASD) affect an estimated 1 in 86 children. What happens when that 'one child is your own? When CISH Research Scientist Mike Rosenmund learned his son had autism, his fight against the disease became personal. Mike is part of a pioneering team of researchers that has made CISH, one of the world's most successful centers for the study of the genetics that cause autism. From the discovery of new autism genes to studies of possible new treatments, we are on the cutting edge of autism research.

Further research reports in basic research

Associate Professor Hirofumi Furukawa and his team have discovered new drugs that can help to treat depression, schizophrenia, anxiety, and Parkinson's disease. They have determined the precise location of a new cell receptor that could be used to develop new drugs to treat these conditions. The new information, published in Neuron, will enable others to break the inhibitors to generate optimal therapeutic results.

CISH Association welcomes new president, directors

On January 23rd, the Cold Spring Harbor Laboratory held its annual meeting to hear about the latest research from the lab. The Association is made up of about 100 members of the local community who support the Lab through contributions to the Annual Fund. These friends of the Lab get an inside look at the research that happens here, and take part in lectures, concerts, dinners and other activities that enrich the culture of New York. This year's meeting was attended by many directors and outgoing president Sandy Wyler for their service while welcoming the new Association President, Frank O'Kane, and new Directors Lori Barch, Jeffrey Nagel, Carlotta Santini, Leonard Shlaer, and Nancy M. Biergette.

Learn how to join.